| Literature DB >> 35733671 |
Margarita R Chetyrkina1, Fedor S Fedorov1, Albert G Nasibulin1,2.
Abstract
Carbon nanotube (CNT) toxicity-related issues provoke many debates in the scientific community. The controversial and disputable data about toxicity doses, proposed hazard effects, and human health concerns significantly restrict CNT applications in biomedical studies, laboratory practices, and industry, creating a barrier for mankind in the way of understanding how exactly the material behaves in contact with living systems. Raising the toxicity question again, many research groups conclude low toxicity of the material and its potential safeness at some doses for contact with biological systems. To get new momentum for researchers working on the intersection of the biological field and nanomaterials, i.e., CNT materials, we systematically reviewed existing studies with in vitro toxicological data to propose exact doses that yield toxic effects, summarize studied cell types for a more thorough comparison, the impact of incubation time, and applied toxicity tests. Using several criteria and different scientific databases, we identified and analyzed nearly 200 original publications forming a "golden core" of the field to propose safe doses of the material based on a statistical analysis of retrieved data. We also differentiated the impact of various forms of CNTs: on a substrate and in the form of dispersion because in both cases, some studies demonstrated good biocompatibility of CNTs. We revealed that CNTs located on a substrate had negligible impact, i.e., 90% of studies report good viability and cell behavior similar to control, therefore CNTs could be considered as a prospective conductive substrate for cell cultivation. In the case of dispersions, our analysis revealed mean values of dose/incubation time to be 4-5 μg mL-1 h-1, which suggested the material to be a suitable candidate for further studies to get a more in-depth understanding of its properties in biointerfaces and offer CNTs as a promising platform for fundamental studies in targeted drug delivery, chemotherapy, tissue engineering, biosensing fields, etc. We hope that the present systematic review will shed light on the current knowledge about CNT toxicity, indicate "dark" spots and offer possible directions for the subsequent studies based on the demonstrated here tabulated and statistical data of doses, cell models, toxicity tests, viability, etc. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35733671 PMCID: PMC9152879 DOI: 10.1039/d2ra02519a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Schematic presentation of CNTs applications and their threat to environment and humans.
Fig. 2Production of CNTs employed for in vitro assessment of toxic effects – comparing industry and research laboratories, i.e., academia. (A) Companies that produced CNTs applied for in vitro toxicity assessment and their world location with two centers: the USA and Asia. (B) The annual number of cytotoxic studies devoted to direct contact through dispersion or substrate included in the statistical analysis in our review. (C) Number of papers where CNTs synthesized by industry (I) or by research laboratories, i.e., academia (A). (D) Types of tubes used in studies: SWCNTs (SW), MWCNTs (MW) or others (CNT fibers or Buckypaper).
Fig. 3Statistics for two crucial parameters greatly varying among in vitro examinations: cell types and applied cytotoxic test. (A) Cell types used in the studies included in the present review analysis; (B) tests used for evaluation of the CNT toxicity in dispersion.
Cytotoxic studies of CNT thin-films substrates for cells
| Type of cells or cell line | Incub. time (hours (h) or days (d)) | Type of CNTs, diameter ( | Synthesis, producer, catalysts, functionalization (F) | Year | Ref. |
|---|---|---|---|---|---|
| Embryonic rat hippocampal neurons | 8 d | MWCNTs, | Catalytic decomposition, ferrocene-xylene, 4-HNE (F) | 2000 |
|
| Osteoblasts | 3, 7 d | MWCNTs, | CVD, Applied Sciences Inc., USA, pyrolytic aromatic hydrocarbon layer (F) | 2002 |
|
| Human osteoblasts, ovine bladder smooth muscle cell, mouse skin fibroblasts, human articular chondrocytes | 1 h | MWCNTs, | CVD, Applied Sciences Inc., USA, pyrolytic aromatic hydrocarbon layer (F) (composite with polycarbonate urethane) | 2003 |
|
| Dissociated cortical cultures from one-day-old Charles River rats | Near 6 d (150 h) | No data about tube parameters | Clusters of CNT, iron nitrate as the catalyst | 2004 |
|
| Fibroblast mouse L929 | 1, 7 d | MWCNTs (vertically aligned), | CVD, Ni catalyst, NanoLab Inc., USA | 2004 |
|
| Hippocampal neurons from 0 to 2 day Sprague-Dawley rats | 7 d | No data about tube parameters | AP-SWCNT, MWCNT-COOH (F), MWCNT with ethylene diamine(F), poly- | 2004 |
|
| Rat astrocyte cells, pheochromocytoma cells, human osteoblast cells (embryo 3T3) mouse fibroblasts | 1 h, 3 d | MWCNTs, | CVD, Applied Sciences Inc., USA, pyrolytic aromatic hydrocarbon layer (F) | 2004 |
|
| Hippocampal neurons | 8, 10 d | MWCNTs, no data about tube parameters | Nanostructured and Amorphous Material (NanoAmor) Inc., USA | 2005 |
|
| Hippocampal neurons | 3, 7 d | SWCNTs, no data about CNT parameters | SWCNT-COOH (F), Carbon Solutions Inc., USA | 2005 |
|
| H19-7 (derived from hippocampi from embryonic day 17 Holtzman rats) | 6 h | MWCNTs (vertically aligned), | CVD, iron catalyst | 2005 |
|
| NG108-15 neuroblastoma × glioma hybrid cells | 3, 5, 10 d | SWCNTs, no data about tube parameters | Arc-discharge, CarboLex Inc., USA | 2005 |
|
| NG108-15 neuroblastoma × glioma hybrid cells | 3, 5, 10 d | SWCNTs, no data about CNT parameters | Arc-discharge, CarboLex Inc., USA | 2006 |
|
| Human osteoblasts hFOB, human fibroblastic line HS-5 | 24, 48 h, 7 d | MWCNTs, no data about tube parameters | Catalytic decomposition on CoO/MgO catalyst | 2006 |
|
| Osteoblasts ROS 17/2.8 cells | 5 d | SWCNTs, | SWCNT-COOH(F); SWCNT-PABS(F); SWCNT-PEG(F); Carbon Solutions Inc., USA | 2006 |
|
| Mouse embryonic neural stem cells | 3, 5, 7 d | SWCNTs, no data about tube parameters | HiPCO, Carbon Nanotechnologies Inc., USA | 2007 |
|
| Hippocampal cultures from 0/3 d old Sprague Dawley rats | 8, 14 d | SWCNTs, no data about tube parameters | HiPCO, Carbon Nanotechnologies Inc., USA | 2007 |
|
| Human skin fibroblasts, Schwann cells from rats, cortical and cerebellar neurons, dorsal root ganglion neurons | 36–48 h, 14 d | MWCNTs, | CVD | 2007 |
|
| Osteoblast | 21 d | MWCNTs, no data about tube parameters | CVD, cobaltous nitrate solution | 2007 |
|
| Immortal NIH3T3, primary, rat hippocampal neural cells | 14, 24 h, 7 d | SWCNTs, no data about tube parameters | Nanoledge Inc., Canada | 2008 |
|
| Fibroblast L929 mouse cells | 2, 24, 48, 72, 96 h | MWCNTs, no data about tube parameters | — | 2008 |
|
| Human osteoblast cells | 7 d | MWCNTs; | CVD, NanoLab Inc., USA | 2008 |
|
| Human collateral cancer cell Caco-2, human breast adenocarcinoma MCF7 and HL-60, primary HA-SMCs | 24, 72, 120 h | — | CVD, NanoLab Inc., USA | 2008 |
|
| Hippocampal neurons of newborn Sprague-Dawley rats | 3 d | SWCNTs, no data about tube parameters | Carbon Solutions Inc., USA | 2009 |
|
| Neural stem cells | 12, 24 h, 7 d | SWCNTs, no data about tube parameters | HiPCO, Carbon Nanotechnologies Inc., USA | 2009 |
|
| Human embryonic stem cells | 1, 3, 5 d | — | — | 2009 |
|
| NIH-3T3 | 24, 48 h | MWNTs | CVD, NanoLab Inc., USA | 2010 |
|
| Human mesenchymal stem cell | 1, 3, 7, 14 d | SWCNTs, no data about tube parameters | Carbon Solutions Inc., USA | 2010 |
|
| Human embryonic stem cells | 1, 7 d | MWCNTs, no data about tube parameters | Sigma-Aldrich Inc., USA | 2010 |
|
| Mouse fibroblast cells | 24, 48, 72, 96 h | MWCNTs, no data about tube parameters | Microwave plasma chamber, Ni or Fe layer | 2010 |
|
| Mouse fibroblast cells | 6, 48, 72 h, 7 d | — | Microwave plasma chamber, Ni or Fe layer | 2012 |
|
| Mouse embryonic fibroblasts, human bronchial epithelial cell line 24 h | 24 h | MWCNTs, | — | 2014 |
|
| Human HCC lines (SNU182 and HUH7) | 3 d | Vertically aligned CNTs, no data about CNT parameters | CVD | 2014 |
|
| Human promyelocytic leukemia cell line HL-60, human 134 histiocytic lymphoma cell line U-937, the human chronic leukemia cell line K-562 | 24, 48, 72 h | — | CVD, NanoLab Inc., USA | 2015 |
|
| Pancreatic adenocarcinoma, PANC-1, AsPC-1, and BxPC-3 cell lines | 1, 4, 8 d | MWCNTs, forest, no data about tube parameters | CVD | 2018 |
|
| Murine L929 fibroblasts, human dermal fibroblast | 1, 3, 7 d | MWCNTs, no data about tube parameters | Nanostructured and Amorphous Material (NanoAmor) Inc., USA | 2021 |
|
| HEK-293 cells, neonatal rat ventricular myocytes (NRVMs), murine Bone marrow derived macrophages, Jurkat cells, SH-SY5Y | 2, 5 d | CNTF, | — | 2021 |
|
Fig. 4Dose (log(μg mL−1)) dependence of viability (a percentage of alive cells after incubation) at various incubation time for (A) different tissues (blue – epithelial, red – connective, green – nervous, purple – muscle), (B) CNTs type (blue – SWCNT, green – MWCNT, red – both). Frequency distribution for (C) dose/time values (μg mL−1 h−1) (black line is a Gaussian distribution, green line shows the maximum), (D) viability values (black line is a Gaussian distribution, red line shows the peak rounded up value). (E) Viability versus dose/time (green and red lines position the maximum frequencies crossing for both characteristics (C and D), viability and dose/time).
Cytotoxic studies of CNTs applied as dispersion
| Type | Cytotoxic test | Incub. time | Dose, viable ( | Cell type | Year | Ref. |
|---|---|---|---|---|---|---|
| SWCNT | Alamar blue | 18 h | 0.24 mg mL−1 | Human epidermal keratinocytes | 2003 |
|
| SWCNT; MWCNT | Alamar blue | 24, 48, 72, 144 h | 144 h 0.16 mg mL−1 | hMSCs | 2008 |
|
| SWCNT (solution-indirect) | Alamar blue | 24, 48, 72 h, 96 h | Indirect 24 h 0.8 mg mL−1 | A549 | 2008 |
|
| MWCNT | Alamar blue | 24 h | BEAS2B IC50 = 7 μg mL; mesothelioma IC50 = 17 μg mL−1 | BEAS2B; mesothelioma | 2012 |
|
| MWCNT | Alamar blue | 24 h | 50 μg mL−1; | BEAS2B | 2013 |
|
| MWCNT | Alamar blue | 24 h | Different data (1 μg mL−1 is safe; other conc varying data) | BEAS2B; MESO1 | 2014 |
|
| MWCNT | Alamar blue | 24 h | 10 mg L−1, | Primary astrocytes | 2015 |
|
| SWCNT; MWCNT | Alamar blue | 24, 48 h | (SW)100 μg mL−1; | THP1 | 2017 |
|
| MWCNT | Alamar blue | 24 h | 24 μg mL−1; | BEAS2B; SAEC | 2019 |
|
| MWCNT | Alamar blue | 24 h | 100 μg mL−1; | Human lymph node endothelial cells | 2020 |
|
| SWCNT | Alamar blue (for substrates contact NIH3T3 and PC12) | 15 min RBC, 3 d | -;- (RBC lysis); | RBC; NIH3T3; PC12 | 2008 |
|
| MWCNT | Alamar blue, LDH | 24 h | BEAS2B 10 μg mL−1 | BEAS2B; mesothelioma; neuroblastoma (IMR32), THP1 | 2012 |
|
| SWCNT; MWCNT | Alamar blue, MTT | 24 h | A549 0.75 mg mL−1 | A549; U937 | 2007 |
|
| SWCNT | Alamar blue, NR, MTT | 24 h | EC50 = 744 ± 91 μg mL−1; with serum > 800 μg mL−1 | A549 | 2007 |
|
| SWCNT | Annexin V + PI | 4 h–24 h | 10–50 μg mL−1, no cells activation | Primary immune cells | 2006 |
|
| SWCNT | Annexin V + PI | 24, 48 h, 72, 96 h | 50 μg mL−1 | A549 | 2007 |
|
| SWCNT; MWCNT | Annexin V + PI | 24, 48 h, 72 h | 48 h EC50 = 450 μg mL−1 (SW); 72 h EC50 = 600 μg mL−1 (MW) | Mononuclear cells | 2012 |
|
| MWCNT | Aqueous one | 24, 96 h | BEAS2B 4 d 200 μg mL−1 | BEAS2B; A549 | 2011 |
|
| MWCNT | CCK8 | 24 h | 50 mg mL−1 | Neuroblastoma (N); HeLa | 2012 |
|
| MWCNTs | CCK8 | 24 h | 40 μg mL−1 | HepG2 | 2016 |
|
| MWCNT | CCK8 | 24, 48 h | 100 μg mL−1 | NIH-3T3 | 2016 |
|
| MWCNT | CCK8 | 72 h (+26 weeks) | For 72 h 1.92 μg cm−2 | HBEC-3KT | 2017 |
|
| MWCNT | CCK8 | 6 h | 64 μg mL−1 V near 60% | HUVECs | 2018 |
|
| SWCNT | CCK8 | 12 h | 50 μg mL−1 | HUVECs | 2018 |
|
| SWCNT | CCK8 | 12 h | 50 μg mL−1 | HUVECs | 2018 |
|
| MWCNT | CCK8 | 24 h | 60 μg mL−1 | HUVECs | 2019 |
|
| MWCNT | CCK8 | 24 h | 64 μg mL−1 | THP-1 | 2019 |
|
| MWCNT | CCK8 | 24 h | 64 μg mL−1 | HUVECs | 2019 |
|
| MWCNT | CCK8 | 24 h | 64 μg mL−1 | SMCs smooth muscle cells | 2019 |
|
| MWCNT | CCK8 | 24 h | 64 μg mL−1 | HUVEC | 2019 |
|
| SWCNT | CellTiter blue assay | 6 h–48 h | -;- (factor increase units) | A549; NHBE | 2008 |
|
| MWCNT | CellTiter blue | 24, 72 h | 24 h 200 μg mL−1, | Raw264.7 | 2012 |
|
| MWCNT | CellTiter-Glo | 24 h | 25 μg mL−1 | Human brain microvasculature endothelial cells | 2017 |
|
| SWCNT | CellTiter-Glo | 72 h | 10 μg mL−1 | HEK293; MCF10A; MRC-5; HepG2 | 2017 |
|
| SWCNT | CyQUANT | 24 h | 25 μg mL−1 | Human lung fibroblasts; HUVEC | 2013 |
|
| SWCNT; MWCNT | Flow cytometry | 24, 48, 72 h | 24 h 100 μg mL−1 | Jurkat | 2008 |
|
| MWCNT | Flow cytometry | 8, 24, 48 h | Jurkat S 100 μg mL−1 | Jurkat; primary splenocytes (S); primary neurons (N) | 2009 |
|
| MWCNT | Flow cytometry | 1 h | 100 μg mL−1 | A549 | 2015 |
|
| MWCNT | Flow cytometry | 24 h | 200 μg mL−1 V near 50% | Normal liver cells | 2015 |
|
| MWCNT | Flow cytometry | 24 h | 120 μg mL−1 | Raw264.7 | 2020 |
|
| SWCNT | Hemocytometer (cells recovery) | Up to 4 d | 50 μg mL−1 – (30% or 85% from control) | Murine lung epithelial cells | 2007 |
|
| MWCNT | Hoechst 33342 + microscope | 24, 48 h | 0.6 μg mL−1 | Human skin fibroblasts | 2005 |
|
| MWCNT | Indirect assay (protein expression) | 24, 48 h | — | HEK keratinocytes | 2006 |
|
| MWCNT | Indirect assay (AP detection kit) | 2, 4 h | — | Mouse embryonic Stem cell | 2007 |
|
| SWCNT | Indirect assay (NO, free radicals, super oxide) | 1–2 h | 0.5 mg mL−1 no changes | Raw 264.7 | 2005 |
|
| SWCNT | Indirect assay (NO, free radicals, super oxide, apoptosis) | 24, 48, 72 h | 30 mg mL−1 | J774; hMDM | 2006 |
|
| SWCNT | Indirect assay (oxidative stress) | 3 h | 10 μg mL−1 ROS increase in 12% | BJ Foreskin cells | 2007 |
|
| MWCNT | LDH | 24 h | 125 ng mL−1 no toxic effects | Human mononuclear cells | 2007 |
|
| MWCNT | LDH | 24 h | — | hMSCs | 2013 |
|
| MWCNT; SWCNT | LDH | 24 h | 40 μg mL−1 | MDMs | 2014 |
|
| MWCNT; SWCNT | LDH | 24 h | 100 μg mL−1 | A549; J774 | 2014 |
|
| MWCNT | LDH | 24 h | 80 μg mL−1 | Met-5A | 2016 |
|
| SWCNT | LDH | 24, 48 h | 2 μg mL−1 | HeLa; HUVEC; Hep2G | 2018 |
|
| MWCNT | LDH | 24 h | — | Mesothelial LP9 | 2020 |
|
| MWCNT | LDH, trypan blue | 24 h | 12 μg mL−1 | Bronchial epithelial primary cells | 2019 |
|
| MWCNT | LDH, CCK8 | 24 h | 100 μg mL−1 | HUVEC | 2014 |
|
| MWCNT | LDH, MTT | 48 h | 300 ng mL−1 | HEK293 | 2010 |
|
| MWCNT | LDH, MTT, WST1, XTT | 1, 72 h | 48 h LDH 100 mg mL−1 | A549 | 2008 |
|
| MWCNT | LDH, trypan blue | 24 h | TC50 = 20–80 μg mL−1 (for both CNT) | A549; Hep3B; HEK | 2010 |
|
| MWCNT | LDH, WST1 | 24 h | EC50 near 200 μg mL−1 | A549 | 2017 |
|
| MWCNT; SWCNT | LDH, WST1 | 24 h | 256 μg mL−1 | 16HBE | 2018 |
|
| MWCNT | LDH; WST8 | 24 h | 32 μg mL−1 | HUVECs | 2017 |
|
| MWCNT | Live/Dead | 12, 24 h | 5 μg mL−1 | Rat LE cells | 2010 |
|
| SWCNT | Microscopy | 6 d | — | Primary neurons (N); primary glia (G) | 2009 |
|
| MWCNT | Microscopy | 48 h | 17 μg mL−1 | DRG; PC12 | 2010 |
|
| MWCNT | Molecular probes cell viability | 24 h | 5.5–55.8 μg mL−1 | Human osteoblasts | 2004 |
|
| SWCNT | MTS | 24, 48, 72 h | 0.04 mg mL−1 | MCF7; human epidermal keratino-s | 2004 |
|
| SWCNT | MTS | 24, 48, 72 h | 40 μg mL−1 | MCF7 | 2015 |
|
| MWCNT | MTS | 24 h | 100 μg mL−1 | A549; lung V79 fibroblasts | 2015 |
|
| MWCNT | MTS | 24 h | 400 μg mL−1 | Raw264.7 | 2016 |
|
| MWCNT | MTS | 24 h | IC50 10 μg mL−1 | A549 | 2021 |
|
| SWCNT | MTS, flow.cyt. | 24 h | 40 μg mL−1 | MCF7 | 2013 |
|
| MWCNT | MTS, LDH | 24 h | 100 μg mL−1 | BEAS2B; RLE6TN; THP1 | 2013 |
|
| MWCNT; SWCNT | MTS, live/dead | 24 h | (MW) 10 μg cm−2 | HAEC | 2012 |
|
| SWCNT | MTS, NR, LDH | 24 h | 100 μg mL−1 resulted in first cytotoxic ef (varied EC50 233 μg mL−1 to 600 μg mL−1) | Caco2 | 2009 |
|
| SWCNT | MTT | 72 h | 20 μg mL−1 | Human epidermal keratino-s; HeLa; A549; H1299 | 2005 |
|
| SWCNT; MWCNT | MTT | 3 h, 6 h | 22.6 μg cm−2 | Alveolar macrophages | 2005 |
|
| SWCNT | MTT | 24 h–120 h | 100 μg mL−1 | HEK293 | 2005 |
|
| SWCNT | MTT | 24, 48 h | 20 μg mL−1 | Human dermal fibroblasts | 2006 |
|
| SWCNT; MWCNT | MTT | 24 h–120 h | 25 μg mL−1 | Human dermis fibroblasts | 2006 |
|
| MWCNT | MTT | 24, 96 h | 0.2 μg mL−1 H596 24 h | H596; H466; Calu-1 | 2006 |
|
| SWCNT | MTT | 3 d | 30 μg mL−1 | Mesothelioma MSTO-211H | 2007 |
|
| SWCNT; MWCNT | MTT | 24 h | 100 μg mL−1 (N) | Neuroblastoma (N); Rat alveolar macrophages (M) | 2007 |
|
| SWCNT | MTT | 6 h, 48 h | 500 mg L−1; Hep3B and HepG2 | Hep3B; HepG2; Panc-1 | 2007 |
|
| SWCNT | MTT | 24, 48, 72 h | 24, 48 h 3.2 μg mL−1 | Astrocytoma 1321N1 | 2008 |
|
| MWCNT | MTT | 24 h | 100 μg mL−1 | HeLa | 2009 |
|
| MWCNT | MTT | 24 h | 17.5 μg mL−1 | Primary cortical cultures | 2009 |
|
| MWCNT | MTT | 24, 48 h | 24 h D384 100 μg mL−1 | A549; astrocytoma D384 | 2010 |
|
| MWCNT; SWCNT | MTT | 48, 72 h (up to 3 w for diff) | 24 h and 48 h 30 μg mL−1, | MSCs | 2010 |
|
| MWCNT | MTT | 72, 144 h | 30 μg mL−1 | A549; Jurkat | 2011 |
|
| SWCNT; MWCNT | MTT | 24, 72, 168 h | (SW) 0.11 mg mL−1 | A549 | 2011 |
|
| MWCNT | MTT | 24 h | 100 μg mL−1 | A549; Raw264.7 | 2011 |
|
| MWCNT | MTT | 24, 48, 72 h | 40 μg mL−1 | NHDF | 2012 |
|
| MWCNT | MTT | 24 h | 100 μg mL−1 | A549 | 2012 |
|
| MWCNT | MTT | 24 h | 6 mg mL−1 for one type | J774 | 2012 |
|
| MWCNT | MTT | 12, 24, 36 h | 24 h 100 μg mL−1 | C6 rat glioma | 2012 |
|
| MWCNT | MTT | 24 h | A549 TC50 = 35.6 μg mL−1; HepG2 TC50 = 33.5 μg mL−1; HEK TC50 = 35 μg mL−1; P407 TC50 = 39 μg mL−1 | A549; HepG2; HEK; P407 | 2014 |
|
| SWCNT | MTT | 24 h | 50 μg mL−1 | A549; MCF7; SKBr3 | 2015 |
|
| MWCNT | MTT | 24 h | 2 μg mL−1, | A549 | 2016 |
|
| MWCNT | MTT | 48 h | 200 μg mL−1 | HT29 | 2017 |
|
| MWCNT | MTT | 48 h | 256 μg mL−1 | A549 | 2019 |
|
| MWCNT; SWCNT | MTT | 48 h | 8 μg mL−1 | A549 | 2020 |
|
| SWCNT | MTT | 24 h | 200 μg mL−1 | A549 | 2020 |
|
| MWCNT | MTT, LDH | 24 h | 40 μg mL−1 | A549 | 2012 |
|
| SWCNT | MTT, LDH | 48 h | IC50 = 87.6 μg mL−1 | HEK293 | 2014 |
|
| MWCNT | MTT, LDH | 24 h | 100 μg mL−1 | Alveolar type-I like cells (TT1), ATII, alveolar macrophages | 2014 |
|
| MWCNT | MTT, LDH | 1, 3 h | — | A549 | 2020 |
|
| MWCNT | MTT, NR | 24 h | EC80 = 2.1 mg L−1 | H295R (adenocarcinoma); T47Dluc | 2014 |
|
| SWCNT | MTT, LDH, WST1 | 24 h | 50 μg mL−1 MTT | A549; HUVEC; alveolar macrophage | 2006 |
|
| MWCNT | MTT, WST1 | 72, 96 h, 1–2 w | 3d 5 μg mL−1 | SH-SY5Y | 2009 |
|
| MWCNT; SWCNT | MTT, LDH | 24, 48 h | 24 h (SW) 300 μg mL−1 | NIH3T3 | 2009 |
|
| SWCNT | MTT, LDH | 24, 48, 72 h | 50 μg mL−1 | HUVEC | 2010 |
|
| SWCNT | MTT, LDH | 24 h | 100 μg mL−1 | PC12 | 2010 |
|
| SWCNT | MTT, LDH; trypan blue | 24 h | 50 μg mL−1 V > 80% | Human umbilical cord MSCs | 2020 |
|
| SWCNT | MTT, WST | 24 h | MTT NR8383 5 μg mL−1 | A549; rat macrophages (NR8383) | 2007 |
|
| SWCNT | NR, MTT | 24 h | 5 μg mL−1 | HUVEC | 2006 |
|
| SWCNT | NR, MTT | 24 h | — | HUVEC | 2006 |
|
| SWCNT | NR, MTT | 96 h | 10 μg mL−1 | hMDM | 2009 |
|
| MWCNT | NR, live/dead | 48 h | 20 μg mL−1 | Macrophages | 2011 |
|
| SWCNT | NR; MTS | 24, 48 h | EC50 = 316 μg mL−1 for 24 h; EC50 = 81 μg mL−1 for 48 h | HUVEC | 2011 |
|
| MWCNT | NR, MTT; live/dead | 96 h | 20 μg mL−1 MTT | hMDM | 2009 |
|
| SWCNT | NR, MTT, alamar blue; aqueous one (AQO) | 24 h | 0.4 μg mL−1 | HEK keratinocytes | 2009 |
|
| SWCNT | Optical microscopy | 12, 24, 48, 60 h | 50 μg mL−1 | HeLa | 2007 |
|
| MWCNT | PI | 6 h | 50 μg mL−1 | A549 | 2017 |
|
| SWCNT; MWCNT | PI, acridine orange | 12, 48 h | 50 μg mL−1 | H1299 | 2019 |
|
| MWCNT | Resazurin assay | 24, 48, 72 h | Raw IC50 > 80 μg cm−2 | Raw264.7; A549; Calu-3; alveolar macrophages | 2016 |
|
| SWCNT | Trypan blue | 24, 48, 72 h | 0.2 mg mL−1 | Rat heart cell | 2005 |
|
| MWCNT | Trypan blue | 24, 48, 72, 96, 120 h | 10 ng per cell 24 h | T Lymphocytes | 2006 |
|
| MWCNT | Trypan blue | 18 h | 40 μg cm−2 | A549 | 2008 |
|
| MWCNT + SWCNT | Trypan blue | 24, 48, 72 h | 24 h 100 μg cm−2 | BEAS2B | 2009 |
|
| MWCNT | Trypan blue | 24 h | 100 μg mL−1 | HUVEC | 2011 |
|
| MWCNT SWCNT | Trypan blue | 24, 48, 72 h | 24 h 100 μg mL−1 | Raw264.7 | 2011 |
|
| SWCNT MWCNT | Trypan blue | 24, 48 h | 48 h BEAS2B 152 μg mL−1 | BEAS2B; MeT5A | 2013 |
|
| SWCNT | Trypan blue | 36, 120 h | 30 μg mL−1 | A549 | 2013 |
|
| SWCNT | Trypan blue | 24, 48 h | 70 μg mL−1 | NIH3T3 | 2015 |
|
| MWCNT | Trypan blue | 13 w | 1.92 μg cm−2 | HBEC-3-KT | 2018 |
|
| MWCNT | Trypan blue | 24, 48 h | 60 μg mL−1 | Primary microglial cells | 2018 |
|
| MWCNT | Trypan blue | 24 h | 0.1 mg mL−1 | HUVECs; human liver hepatocellular carcinoma | 2020 |
|
| MWCNT | Trypan blue, EZ-cytox assay | 24 h | EC20 for pristine 3 mg mL−1; EC20 for OH near 6 mg mL−1 | BEAS2B; HepG2 | 2016 |
|
| MWCNT (BP) | Trypan blue, NR | 48, 72 h | — | Blood lymphocytes | 2015 |
|
| MWCNT + fibers | Trypan blue, MTT | 24 h | 1 mg mL−1 | NIH3T3 | 2008 |
|
| MWCNT | Trypan blue, LDH | 24 h | 125 μg cm−2 | Mesothelial cells | 2008 |
|
| SWCNT | Trypan blue, LDH | 24, 48, 72 h | 50 μg mL−1 | T Lymphocytes | 2008 |
|
| MWCNT | Trypan blue, live/dead assay | 24, 48, 72 h | 72 h 50 μg mL−1 | THP-1 | 2016 |
|
| MWCNT | Trypan blue, WST1 | 24, 48, 72 h | 72 h 100 μg mL−1 | HPBCs (human peripheral blood cells) | 2016 |
|
| MWCNT | Trypan blue, WST1 | 24 h | A549 40 μg mL−1 | A549; BEAS2B | 2016 |
|
| MWCNT | Trypan blue, WST8, CCK8 | 168 h | 100 μg mL−1 | Dendritic cells | 2009 |
|
| MWCNT | WST1 | 24 h | GI50 = 0.0135% | NHBE | 2012 |
|
| SWCNT | WST1 | 72 h | 20 μg mL−1 | hMSCs | 2019 |
|
| MWCNT (+fibers) | WST1 | 24 h | 24 μg mL−1 | BEAS2B | 2020 |
|
| MWCNT | WST1, CCK8 | 24 h | 100 μg mL−1 | Human bone osteosarcoma; human gingival fibroblasts (HGF-1) | 2016 |
|
| MWCNT SWCNT | WST1, LDH | 24 h | 150 μg per 106 cells | HAEC | 2009 |
|
| MWCNT | WST8 | 24 h | IC50 = 12 μg mL−1 | BEAS2B; CHO-K1 | 2010 |
|
| MWCNT | WST8 | 24 h | EC50 near 30 μg cm−2 | A549; HepG2 | 2019 |
|
| MWCNT | WST8, MTT | 16, 32 h | 24 h LC50 = 26 μg mL−1; 32 h LC50 = 22 μg mL−1 | J774.1; CHO-K1 | 2008 |
|